Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript

2025-12-08
Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations December 8, 2025 7:01 PM ESTCompany...

Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies

2025-11-13
FORT WORTH, Texas, November 13, 2025--Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies

Omnicell (OMCL): Rebound Sparks Fresh Look at Valuation and Growth Prospects

2025-11-13
Omnicell (OMCL) shares have been on the move this month, with the stock gaining 25% over the past month and up 17% in the past 3 months. Recent performance has caught the eye of investors, particularly following an extended period of declines. See our latest analysis for Omnicell. While Omnicell’s share price has rebounded sharply over the past month, recent gains only partially offset a much tougher run for long-term shareholders. The 1-year total shareholder return is still down nearly 23%...

Wall Street Analysts Believe Omnicell (OMCL) Could Rally 34.53%: Here's is How to Trade

2025-11-10
The consensus price target hints at a 34.5% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

3 Russell 2000 Stocks with Warning Signs

2025-11-07
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

OMCL vs. HIMS: Which Stock Is the Better Value Option?

2025-11-04
OMCL vs. HIMS: Which Stock Is the Better Value Option?

Earnings Estimates Moving Higher for Omnicell (OMCL): Time to Buy?

2025-11-03
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?

2025-11-03
OMCL vs. HIMS: Which Stock Is the Better Value Option?

Omnicell (OMCL) Is Up 7.9% After Q3 Beat and Outlook Raise Is the Growth Story Gaining Momentum?

2025-11-02
In the past week, Omnicell released its third-quarter 2025 results, reporting revenues of US$310.63 million, up from US$282.42 million a year earlier, and raising full-year revenue guidance to US$1.18 billion–US$1.19 billion. Omnicell also completed a substantial share repurchase program and highlighted accelerating adoption of its intelligent medication management platform as key drivers of its financial results. We'll explore how Omnicell's robust quarterly performance and upwardly revised...

Why Omnicell Stock Crushed the Market Today

2025-10-30
The company continues to benefit from demand for its next-generation healthcare tech offerings.